ערך בספרים למניה: kaziatherapeutics.com (KZIA)

Kazia Therapeutics (KZIA) plans to generate revenue from the launch of paxalisib for the therapy of aggressive brain tumors. On GURU.Markets, the book value indicator reflects the issuer's actual assets, where 2.74 is recorded as the baseline value. Development is being conducted through global partnerships with neuro-oncologists, targeting the underserved orphan drug market and international access programs.

The absence of proprietary manufacturing plants and the utilization of CMO contract sites minimize capital expenditures for Kazia Therapeutics (KZIA), shifting the valuation focus toward liquid assets. This balance sheet valuation on a per-share basis measures residual capital net of intangible revaluations, allowing investors to monitor the real value of their stake and detect hidden write-downs in a timely manner via the price action on the chart.